Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Nawar A, Latif"'
Publikováno v:
Gynecologic Oncology Reports, Vol 43, Iss , Pp 101063- (2022)
Background: The 5-factor modified frailty index (mFI-5) has been validated against the original 11-factor modified frailty index in gynecologic surgery, however its utility has not been evaluated between benign versus gynecologic oncology patient pop
Externí odkaz:
https://doaj.org/article/0fcdc646d3134cc0bee5af89e060d522
Autor:
Dimitrios Nasioudis, Emily M. Ko, Ashley F. Haggerty, Robert L. Giuntoli, II, Robert A. Burger, Mark A. Morgan, Nawar A. Latif
Publikováno v:
Gynecologic Oncology Reports, Vol 28, Iss , Pp 86-90 (2019)
Abstact: Objective: To evaluate the prognostic significance of isolated distant lymph node metastases in comparison to other metastatic sites and stage IIIC disease. Methods: The National Cancer Data Base was accessed and patients diagnosed between 2
Externí odkaz:
https://doaj.org/article/f14a9bdd7c8f461183cd05b5a7497417
Autor:
Dimitrios Nasioudis, Emily M. Ko, Ashley F. Haggerty, Robert L. Giuntoli, II, Robert A. Burger, Mark A. Morgan, Nawar A. Latif
Publikováno v:
Gynecologic Oncology Reports, Vol 28, Iss , Pp 145-148 (2019)
Objective: The aim of the present study was to investigate the patterns of use and prognostic significance of adjuvant chemotherapy (CT) for patients with stage IC ovarian granulosa cell tumors (GCTs). Methods: We identified patients with stage IC GC
Externí odkaz:
https://doaj.org/article/d7279204f4cd4397ba2d1a935e9a0b5b
Autor:
Dimitrios, Nasioudis, Nawar A, Latif, Emily M, Ko, Lori, Cory, Sarah H, Kim, Fiona, Simpkins, Mark A, Morgan, Robert L, Giuntoli
Publikováno v:
Gynecologic Oncology. 169:41-46
Investigate outcomes for advanced stage epithelial ovarian cancer (EOC) patients based on facility-level utilization of neoadjuvant chemotherapy (NACT).Stage III-IV EOC patients diagnosed between 2010 and 2016 were identified in the National Cancer D
Autor:
Anish A. Butala, MD, Roshal R. Patel, BA, Shwetha Manjunath, MD, Nawar A. Latif, MD, MPH, MSCE, Ashley F. Haggerty, MD, MSCE, Joshua A. Jones, MD, FAAHPM, Neil K. Taunk, MD, MSCTS
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 1, Pp 100624- (2021)
Purpose: Metastatic, persistent, or recurrent epithelial ovarian cancer (MPR-EOC) remains a significant threat to patient mortality despite advances in novel targeted agents. Radiation therapy (RT) is often used as a palliative option. We report outc
Externí odkaz:
https://doaj.org/article/2e90256a29474ba78e82607157678361
Autor:
Dimitrios, Nasioudis, Neil K, Taunk, Emily M, Ko, Ashley F, Haggerty, Lori, Cory, Robert L, Giuntoli, Sarah H, Kim, Nawar A, Latif
Publikováno v:
American Journal of Clinical Oncology. 45:373-378
Evaluate whether the addition of external beam radiation (EBRT) to adjuvant chemotherapy with or without vaginal brachytherapy is associated with better survival for patients with stage IIIC endometrioid endometrial carcinoma.Patients diagnosed betwe
Autor:
Dimitrios Nasioudis, Spyridon A Mastroyannis, Emily M Ko, Ashley F Haggerty, Lori Cory, Robert L Giuntoli, Sarah H Kim, Nawar A Latif
Publikováno v:
International Journal of Gynecologic Cancer. 32:1355-1360
ObjectiveTo investigate the utilization and outcomes of ovarian preservation for premenopausal patients with International Federation of Gynecology and Obstetrics (FIGO) stage I grade 2 and 3 endometrioid endometrial carcinoma undergoing hysterectomy
Autor:
Fiona Simpkins, Lilie L. Lin, Robert H. Mach, David A. Mankoff, Robert K. Doot, Gordon B. Mills, Quy Cao, Fang Liu, Shannon M. Lanzo, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Benjamin Ferman, Chia-Ju Hsieh, Drew A. Torigian, Joanna K. Weeks, Sergey Medvedv, Hyoung Kim, Mehran Makvandi, Sarah B. Gitto, Austin R. Pantel
PDX models treated with PARPi therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b709fce70ec5b232ee9c62bef4bcd4c
https://doi.org/10.1158/1078-0432.22632998
https://doi.org/10.1158/1078-0432.22632998
Autor:
Fiona Simpkins, Lilie L. Lin, Robert H. Mach, David A. Mankoff, Robert K. Doot, Gordon B. Mills, Quy Cao, Fang Liu, Shannon M. Lanzo, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Benjamin Ferman, Chia-Ju Hsieh, Drew A. Torigian, Joanna K. Weeks, Sergey Medvedv, Hyoung Kim, Mehran Makvandi, Sarah B. Gitto, Austin R. Pantel
Purpose:PARP inhibitors have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi. Biomarkers to predict response are needed. [18F]Fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca3e6b9627e18387a2ff8484044373b
https://doi.org/10.1158/1078-0432.c.6532755.v2
https://doi.org/10.1158/1078-0432.c.6532755.v2
Autor:
Fiona Simpkins, Lilie L. Lin, Robert H. Mach, David A. Mankoff, Robert K. Doot, Gordon B. Mills, Quy Cao, Fang Liu, Shannon M. Lanzo, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Benjamin Ferman, Chia-Ju Hsieh, Drew A. Torigian, Joanna K. Weeks, Sergey Medvedv, Hyoung Kim, Mehran Makvandi, Sarah B. Gitto, Austin R. Pantel
PARPi treatment and response.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469462e32843161ef29dd7932d404d3e
https://doi.org/10.1158/1078-0432.22632977
https://doi.org/10.1158/1078-0432.22632977